Research programme: antibacterials - AMRI/Genentech

Drug Profile

Research programme: antibacterials - AMRI/Genentech

Alternative Names: AMR-BAC-1

Latest Information Update: 12 Sep 2016

Price : $50

At a glance

  • Originator AMRI
  • Class Anti-infectives; Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 12 Sep 2016 Preclinical development is ongoing in USA (AMRI pipeline, September 2016)
  • 05 Jan 2011 Genentech has received an exclusive license from AMRI to develop and commercialise antibacterial candidates identified from AMRI's antibacterial research programme
  • 09 Feb 2009 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top